Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop Trial Melanoma
NL-OMON59700Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pembrolizumab and nivolumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Rate of ongoing response at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59700.